| Title |
Cannabinoids and Schizophrenia: Risks and Therapeutic Potential
|
|---|---|
| Published in |
Neurotherapeutics, October 2015
|
| DOI | 10.1007/s13311-015-0382-6 |
| Pubmed ID | |
| Authors |
Marc W Manseau, Donald C Goff |
| Abstract |
A convergence of evidence shows that use of Cannabis sativa is associated with increased risk of developing psychotic disorders, including schizophrenia, and earlier age at which psychotic symptoms first manifest. Cannabis exposure during adolescence is most strongly associated with the onset of psychosis amongst those who are particularly vulnerable, such as those who have been exposed to child abuse and those with family histories of schizophrenia. Schizophrenia that develops after cannabis use may have a unique clinical phenotype, and several genetic polymorphisms may modulate the relationship between cannabis use and psychosis. The endocannabinoid system has been implicated in psychosis both related and unrelated to cannabis exposure, and studying this system holds potential to increase understanding of the pathophysiology of schizophrenia. Anandamide signaling in the central nervous system may be particularly important. Δ(9)-Tetrahydrocannabinol in cannabis can cause symptoms of schizophrenia when acutely administered, and cannabidiol (CBD), another compound in cannabis, can counter many of these effects. CBD may have therapeutic potential for the treatment of psychosis following cannabis use, as well as schizophrenia, possibly with better tolerability than current antipsychotic treatments. CBD may also have anti-inflammatory and neuroprotective properties. Establishing the role of CBD and other CBD-based compounds in treating psychotic disorders will require further human research. |
X Demographics
The data shown below were collected from the profiles of 54 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 11 | 20% |
| United States | 3 | 6% |
| Greece | 1 | 2% |
| United Kingdom | 1 | 2% |
| Brazil | 1 | 2% |
| Canada | 1 | 2% |
| Spain | 1 | 2% |
| Unknown | 35 | 65% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 47 | 87% |
| Practitioners (doctors, other healthcare professionals) | 4 | 7% |
| Scientists | 3 | 6% |
Mendeley readers
The data shown below were compiled from readership statistics for 334 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | <1% |
| United States | 1 | <1% |
| Brazil | 1 | <1% |
| Unknown | 331 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 63 | 19% |
| Researcher | 43 | 13% |
| Student > Master | 40 | 12% |
| Other | 22 | 7% |
| Student > Ph. D. Student | 19 | 6% |
| Other | 55 | 16% |
| Unknown | 92 | 28% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 59 | 18% |
| Neuroscience | 35 | 10% |
| Psychology | 34 | 10% |
| Agricultural and Biological Sciences | 19 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 19 | 6% |
| Other | 65 | 19% |
| Unknown | 103 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 64. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 May 2024.
All research outputs
#696,181
of 26,052,823 outputs
Outputs from Neurotherapeutics
#50
of 1,327 outputs
Outputs of similar age
#9,710
of 288,097 outputs
Outputs of similar age from Neurotherapeutics
#6
of 19 outputs
Altmetric has tracked 26,052,823 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,327 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 18.7. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 288,097 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 19 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 68% of its contemporaries.